Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022
Synopsis

Enterovirus D68 in Hospitalized Children, Barcelona, Spain, 2014–2021

Cristina Andrés1, Jorgina Vila1, Anna Creus-Costa, Maria Piñana, Alejandra González-Sánchez, Juliana Esperalba, Maria Gema Codina, Carla Castillo, Maria Carmen Martín, Francisco Fuentes, Susana Rubio, Karen García-Comuñas, Rodrigo Vásquez-Mercado, Narcís Saubi, Carlos Rodrigo, Tomàs PumarolaComments to Author , and Andrés Antón
Author affiliations: Hospital Universitari Vall d’Hebron, Vall d’Hebron Research Institute, Barcelona, Spain (C. Andrés, J. Vila, A. Creus-Costa, M. Piñana, A. González-Sánchez, J. Esperalba, M.G. Codina, C. Castillo, M. Carmen Martín, F. Fuentes, S. Rubio, K. García-Comuñas, R. Vásquez-Mercado, N. Saubi, C. Rodrigo, T. Pumarola, A. Antón); CIBER de Enfermedades Infecciosas, Instituto de SaludCarlos III, Madrid, Spain (C. Andrés, M. Piñana, A. González-Sánchez, J. Esperalba, M.G. Codina, N. Saubi, T. Pumarola, A. Antón); Hospital Universitari Germans Trias i Pujol, Barcelona (C. Rodrigo)

Main Article

Table 2

Demographic and clinical characteristics of patients in study of enterovirus D68 in hospitalized children, Barcelona, Spain, 2014–2021*

Characteristic Hospitalized, no. (%)† Outpatient, no. (%)
Sex
M 44 (57.9) 47/82 (57.3)
F
 56 (42.1)
 35 (42.7)
Age, y
<2 24 (31.6) 24 (29.3)
2–4 34 (44.7) 34 (41.4)
>5
 18 (23.7)
 24 (29.3)
Signs/symptoms‡
LRTI 56 (73.6) 45 (54.9)
>24 mo 40 (71.4) 36 (80.0)
<24 mo 16 (28.6) 9 (20.0)
URTI 10 (13.2) 27 (32.9)
Other
 10 (13.2)
 10 (12.2)
Treatment for LRTI
Chronic respiratory comorbidities 28/56 (50) 20/45 (44.4)
Asthma-directed therapies
β2 agonists 52/56 (92.9) 43/45 (95.6)
Systemic corticosteroids 51/56 (91.1) 34/45 (75.6)
Hospitalization for LRTI
Hospital length of stay, d§ 3 (1–5) NA
Respiratory support§
 44 (78.6)
 NA
Maximum respiratory support required¶
Conventional oxygen 23 (52.3) NA
HFNC 13 (29.5) NA
NIMV 6 (13.6) NA
IMV 1 (2.3) NA
ECMO
 1 (2.3)
 NA
Duration of respiratory support§¶# 3 (1–4)
PICU admission 9 (11.8) NA
PICU length of stay, d§ 4 (2–9) NA

*Units of measure are no. (%) unless otherwise indicated. ECMO, extracorporeal membrane oxygenation; HFNC, high-flow nasal cannula; IMV, invasive mechanical ventilation; LRTI, lower respiratory tract infection; NA, not applicable; NIMV, noninvasive mechanical ventilation; PICU, pediatric intensive care unit; URTI, upper respiratory tract infection. †Percentages are calculated vertically, according to the total cases. ‡The main symptom at time of hospital admission or consultation. §For continuous variables, means and interquartile ranges are indicated. ¶Three patients received home mechanical ventilation and required increased respiratory support during hospitalization. #Excludes the 3 patients with home mechanical ventilation and the patient who received ECMO.

Main Article

1These authors contributed equally to this article.

Page created: June 01, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external